Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:ARZ CVE:PA CVE:SCA CVE:WHN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARZAralez PharmaceuticalsC$0.00C$0.29▼C$3.72C$28.89MN/A79,103 shs274,400 shsPAPalaminaC$0.12C$0.10C$0.09▼C$0.29C$7.78M2.3841,994 shs64,400 shsSCASavary GoldC$0.12-4.2%C$0.12C$0.04▼C$0.13C$29.40MN/A830,838 shs204,500 shsWHNWesthaven GoldC$0.18-2.8%C$0.14C$0.09▼C$0.21C$29.85M1.23179,371 shs78,900 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARZAralez Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PAPalamina0.00%+14.29%+14.29%+33.33%-20.00%SCASavary Gold0.00%0.00%0.00%0.00%0.00%WHNWesthaven Gold-2.78%-2.78%+16.67%+16.67%+9.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARZAralez PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APAPalaminaN/AN/AN/AN/AN/AN/AN/AN/ASCASavary GoldN/AN/AN/AN/AN/AN/AN/AN/AWHNWesthaven GoldN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARZAralez Pharmaceuticals 0.00N/AN/AN/APAPalamina 0.00N/AN/AN/ASCASavary Gold 0.00N/AN/AN/AWHNWesthaven Gold 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARZAralez PharmaceuticalsN/AN/AN/AN/AN/AN/APAPalaminaC$0.0018,824,896,117,178,900,000.00C$0.01 per share14.17C$0.01 per share8.07SCASavary GoldN/AN/AC$0.01 per share14.38C$0.05 per shareN/AWHNWesthaven GoldN/AN/AC$0.00 per share91.25C$0.22 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARZAralez PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/APAPalamina-C$1.78M-C$0.03N/A∞N/A-429,842,450,360,536,000,000.00%-92.87%-87.90%N/ASCASavary GoldN/A-C$0.00N/A∞N/AN/AN/AN/AN/AWHNWesthaven Gold-C$2.92M-C$0.02N/A∞N/AN/A-7.76%-3.84%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARZAralez PharmaceuticalsN/AN/AN/AN/AN/APAPalaminaN/AN/AN/AN/AN/ASCASavary GoldN/AN/AN/AN/AN/AWHNWesthaven GoldN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARZAralez PharmaceuticalsN/AN/AN/APAPalaminaN/A2.141.30SCASavary GoldN/A10.0610.04WHNWesthaven Gold0.460.071.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARZAralez PharmaceuticalsN/APAPalaminaN/ASCASavary GoldN/AWHNWesthaven Gold5.26%Insider OwnershipCompanyInsider OwnershipARZAralez PharmaceuticalsN/APAPalamina24.12%SCASavary GoldN/AWHNWesthaven Gold21.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARZAralez Pharmaceuticals4,50067.19 millionN/ANot OptionablePAPalaminaN/A64.81 millionN/ANot OptionableSCASavary Gold1,228255.63 millionN/ANot OptionableWHNWesthaven GoldN/A170.55 millionN/ANot OptionablePA, WHN, SCA, and ARZ HeadlinesRecent News About These CompaniesWesthaven Gold (CVE:WHN) Stock Price Up 31% - What's Next?July 8, 2025 | americanbankingnews.comWesthaven Gold Closes Non-Brokered Private Placement with Eric Sprott and Earthlabs, for Gross Proceeds of $3.16 MillionJuly 4, 2025 | juniorminingnetwork.comWesthaven Announces Voting Results From 2025 Annual General Meeting - Yahoo FinanceJune 26, 2025 | finance.yahoo.comWesthaven Gold shareholders approve all motions at annual meetingJune 26, 2025 | investing.comWesthaven Gold Corp.: Westhaven Announces Voting Results From 2025 Annual General MeetingJune 25, 2025 | finanznachrichten.deWHN:CA Westhaven Gold Corp.June 20, 2025 | seekingalpha.comWesthaven Commences Summer Drill Program On The Shovelnose Gold Project, Southern British ColumbiaJune 19, 2025 | theglobeandmail.comStockTalk | Gold Report: Junior miners building convictionJune 18, 2025 | msn.comEric Sprott to invest in Westhaven GoldJune 16, 2025 | msn.comWesthaven Gold receives $2.3M investment from Sprott, EarthLabsJune 16, 2025 | mining.comWesthaven Gold Announces Non-Brokered Private Placement With Eric Sprott and Earthlabs, for Gross Proceeds of $3.16 MillionJune 16, 2025 | juniorminingnetwork.comThomas and Thomas buying at Westhaven Gold (WHN)May 22, 2025 | theglobeandmail.comWesthaven Gold Commences Summer Program and Provides Exploration Update on Spences Bridge Gold Belt ProjectsMay 22, 2025 | juniorminingnetwork.comWesthaven Gold Corp.: Westhaven Commences Summer Program and Provides Exploration Update on Spences Bridge Gold Belt ProjectsMay 21, 2025 | finanznachrichten.deWesthaven Completes Brokered Private Placement for Gross Proceeds of $4.6 MillionMay 15, 2025 | finance.yahoo.comWesthaven files technical report supporting Shovelnose gold projectApril 23, 2025 | canadianminingjournal.comCWesthaven Gold Announces Leadership Changes; Appoints Armstrong President & CEOMarch 31, 2025 | juniorminingnetwork.comDavid Grenville Thomas buying at Westhaven Gold (WHN)March 12, 2025 | theglobeandmail.comWesthaven Gold doubles value of Shovelnose property in British ColumbiaMarch 3, 2025 | mining.comAME JV video: Industry backers give ‘stamp of approval’ to Westhaven Gold in BCFebruary 5, 2025 | northernminer.comNMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseWhy Quantum Computing Inc. Is the Quiet Winner in Quantum StocksBy Jeffrey Neal Johnson | June 18, 2025View Why Quantum Computing Inc. Is the Quiet Winner in Quantum StocksD-Wave Is Rising Again Despite Dilution—What’s the Deal?By Nathan Reiff | July 7, 2025View D-Wave Is Rising Again Despite Dilution—What’s the Deal?PA, WHN, SCA, and ARZ Company DescriptionsAralez Pharmaceuticals TSE:ARZAralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.Palamina CVE:PAC$0.12 0.00 (0.00%) As of 07/15/2025 11:38 AM EasternPalamina Corp. engages in the exploration of mineral deposits in Peru and Mexico. It explores for gold, copper, and silver deposits. The company owns interests in the Usicayos, Panorama, Galena, Bendi, Cori, Yin Inca, Gaban, Yang, and Tinka projects located in Peru. Palamina Corp. was incorporated in 2015 and is headquartered in Toronto, Canada.Savary Gold CVE:SCAC$0.12 -0.01 (-4.17%) As of 05/2/2019Savary Gold Corp. engages in the exploration and evaluation of gold properties in West Africa. Its principal project is the Karankasso project that consists of five exploration licenses covering a total area of 688 square kilometers located in the Houndé Gold Belt in Burkina Faso. The company was formerly known as Savary Capital Corp. and changed its name to Savary Gold Corp. in September 2012. Savary Gold Corp. was incorporated in 2008 and is headquartered in Toronto, Canada.Westhaven Gold CVE:WHNC$0.18 -0.01 (-2.78%) As of 07/15/2025 02:57 PM EasternWesthaven Gold Corp., a junior exploration company, engages in the acquisition, exploration, and development of resource properties in Canada. The company primarily explores for gold and silver deposits. The company was formerly known as Westhaven Ventures Inc. and changed its name to Westhaven Gold Corp. in June 2020. Westhaven Gold Corp. was incorporated in 1998 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
